Streetbeat News

Regulatory

BDRX

Biodexa Pharmaceuticals PLC has regained compliance with Nasdaq's $1.00 minimum bid price requirement, ensuring its continued listing on the exchange.

Portfolio Pulse from

November 12, 2024 | 2:00 pm

PEGY

Pineapple Energy Inc. has regained compliance with Nasdaq's minimum bid price requirements, ensuring its continued listing on the Nasdaq Capital Market.

Portfolio Pulse from

November 12, 2024 | 2:00 pm

PLUG

Plug Power reported a larger-than-expected loss for the third quarter, and the potential impact of a new administration could lead to a less favorable environment for green energy companies.

Portfolio Pulse from

November 12, 2024 | 1:45 pm

PLTR

Mike Gallagher, head of defense at Palantir and former U.S. Congressman, discusses the need for an aggressive reform agenda for the next Defense Secretary. He also talks about the geopolitical threats facing President-elect Trump in his second term.

Portfolio Pulse from

November 12, 2024 | 1:45 pm

IVVD

Invivyd, Inc. has released preprints on MedRxiv and BioRxiv detailing the CANOPY Phase 3 trial data for pemivibart, a monoclonal antibody for COVID-19 prophylaxis, showing long-term protection against JN.1 sublineages.

Portfolio Pulse from

November 12, 2024 | 1:45 pm

CYBCF

Cybeats Technologies Corp. updates on its engagement with the U.S. Army, highlighting a new mandate for Software Bills of Materials (SBOMs) from vendors by February 2025. This positions Cybeats to potentially support U.S. military branches and defense contractors.

Portfolio Pulse from

November 12, 2024 | 1:45 pm

RSLS

ReShape Lifesciences has received Health Canada approval for its next-generation Lap-Band 2.0 FLEX, potentially boosting its market presence and sales in Canada.

Portfolio Pulse from

November 12, 2024 | 1:45 pm

MBIO

NDAQ

Mustang Bio has received a positive listing determination from Nasdaq, granting an extension to meet compliance criteria for continued listing. The company has until January 31, 2025, to meet the $1.00 bid price requirement and until February 18, 2025, to meet the $2.5 million stockholders' equity requirement.

Portfolio Pulse from

November 12, 2024 | 1:45 pm

ACNB

ACNB Corporation has received all necessary regulatory approvals to acquire Traditions Bancorp, Inc., marking a significant step in the acquisition process.

Portfolio Pulse from

November 12, 2024 | 1:45 pm

ICPT

The U.S. FDA has declined full approval for Intercept Pharmaceuticals' liver disease drug, casting uncertainty on its market future.

Portfolio Pulse from

November 12, 2024 | 1:30 pm